Optimizing Cardiovascular Outcomes in Type 2 Diabetes: Early Initiation of Dapagliflozin and Sitagliptin From a Cardiologist's Perspective.
This practical guidance document provides valuable insights from leading cardiologists that would support clinicians in selecting the synergistic combination SGLT2i + DPP4i (dapagliflozin + sitagliptin) FDC as an appropriate treatment choice in early intensive therapy in managing people with T2DM and CVD risk for better patient outcomes. The expert opinion in this guidance builds on the established guideline recommendations on FDC of SGLT2i and DPP4i.
Authors
- Rohan Kesarkar
- Peeyush Jain (ORCID: https://orcid.org/0000-0002-3710-4896)
- Ashish Prasad (ORCID: https://orcid.org/0000-0002-8937-5209)
- K Jaishankar
- D. Lachikarathman
- Rajeev Garg (ORCID: https://orcid.org/0000-0002-1949-8019)
- Abhijit Kulkarni (ORCID: https://orcid.org/0000-0001-9045-0475)
- Vivek Mahajan
- R Ravindran
- Pankaj Kumar Sarkar
- Johann Christopher
- Sunil Sathe
- Abhijit Pednekar
Institutions
- Fortis Healthcare (IN)
- Aware Global Hospital (IN)
- CARE Hospitals (IN)
- Sri Jayadeva Institute of Cardiovascular Sciences and Research (IN)
- Diabetes Care and Research Foundation (IN)
- Fortis Escorts Heart Institute (IN)
- USV (India) (IN)
- Apollo Hospitals (IN)
- MedStar Heart & Vascular Institute (US)
- Manipal Hospital (IN)
- Medical College and Hospital, Kolkata (IN)
- Ragas Dental College & Hospital (IN)
Publication Details
- Journal
- PubMed
- Published
- 2025-04-01
- DOI
- https://doi.org/10.7759/cureus.81858
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00